Market closedNon-fractionalADR
Ascendis Pharma/ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ticker
ASND
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Hellerup, Denmark
Employees
879
Website
ascendispharma.dk
Ascendis Pharma Metrics
BasicAdvanced
$7.9B
Market cap
-
P/E ratio
-$9.63
EPS
0.59
Beta
-
Dividend rate
Price and volume
Market cap
$7.9B
Beta
0.59
52-week high
$161.00
52-week low
$85.08
Average daily volume
7.8
Financial strength
Current ratio
0.831
Quick ratio
0.54
Interest coverage (TTM)
-2.73%
Management effectiveness
Return on assets (TTM)
-56.71%
Return on investment (TTM)
-130.03%
Valuation
Price to revenue (TTM)
22.053
Growth
Revenue change (TTM)
322.18%
Earnings per share change (TTM)
12.65%
3-year revenue growth (CAGR)
237.26%
What the Analysts think about Ascendis Pharma
Analyst Ratings
Majority rating from 15 analysts.
Ascendis Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€96M
-30.43%
Net income
-€131M
50.92%
Profit margin
-136.74%
116.94%
Ascendis Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€2.16
-€2.88
-€1.54
-€2.30
-
Expected
-€2.59
-€2.38
-€2.03
-€1.50
-€1.37
Surprise
-16.62%
21.08%
-24.02%
53.09%
-
Ascendis Pharma News
AllArticlesVideos
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
GlobeNewsWire·1 month ago
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·2 months ago
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $7.9B as of July 27, 2024.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of July 27, 2024.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ascendis Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.